Trial · NCT02432066
Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions
NCT02432066, Phase 2, Withdrawn, University of Florida
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions. Trials, record NCT02432066. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02432066
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions
- NCT number
- NCT02432066
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- University of Florida
- Conditions
- Tobacco Use Disorder
- Interventions
- GTS-21, Placebo
- First posted
- 2015-05-01
- Last updated
- 2019-03-25
Source ClinicalTrials.gov
Registered outcomes66
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Reported Nicotine Use from baseline at weeks 1, 2, 3, 4, 5, 6, 7, 8 | Change in baseline at Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8 | Nicotine use will be assessed using Timeline Followback procedures. Nicotine use will be reported to a trained interviewer using a Timeline Followback calendar, facilitated by calendars distributed to participants. |
| Primary | Change in Carbon Monoxide (CO) from baseline at weeks 5, 8 | Change in baseline at Week 5, Week 8 | Expired Carbon Monoxide levels will be quantified in parts per million. |
| Primary | Change in Urine Cotinine (COT) from baseline at weeks 5, 8 | Change in baseline at Week 5, Week 8 | Cotinine excreted in urine will be quantified in ng/mL |
| Secondary | Change in Beck Depression Inventory - II (BDI-II) from baseline at weeks 5, 8 | Change in baseline at Week 5, Week 8 | The Beck Depression Inventory will be used to quantify depressive symptomatology. The measure is a 21-item, self-report, multiple-choice inventory, with scores ranging from 0-63. |
| Secondary | Change in State Anxiety Inventory (AI) from baseline at weeks 5, 8 | Change in baseline at Week 5, Week 8 | The State Anxiety Inventory will be used to quantify anxiety symptomatology. The measure is a 20-item, self-report, multiple-choice inventory, with scores ranging from 20-80. |
| Secondary | Change in State Anger (ANG-S) from baseline at weeks 5, 8 | Change in baseline at Week 5, Week 8 | The Spielberger State Anger Inventory will be used to assess state anger. The measure is a 20-item, self-report, multiple-choice inventory, with scores ranging from 20-80. |
| Secondary | Pill Count - Week 1 | Week 1 | Medication compliance will be assessed with pill counts. |
| Secondary | Pill Count - Week 5 | Week 5 | Medication compliance will be assessed with pill counts. |
| Secondary | Pill Count - Week 8 | Week 8 | Medication compliance will be assessed with pill counts. |
| Secondary | Change in Minnesota Withdrawal Scale from baseline at weeks 1, 2, 3, 4, 5, 6, 7, 8 | Change in baseline at Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8 | The Minnesota Withdrawal Scale measures self-reported severity of nicotine withdrawal. The measure has 15 items, with five possible responses (0-5), thus scores on the scale range from 0 to 60. |
1 to 10 of 66Source ClinicalTrials.gov
See all 66 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R21DA038286 | Effects of GTS-21 on smoking behavior and neurocognitive function | NIXON, SARA JO | UNIVERSITY OF FLORIDA | NATIONAL INSTITUTE ON DRUG ABUSE | 2015 to 2016 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests10
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Secondary outcome | ConductCognition |
| 2-Back Task | Secondary outcome | ConductCognition |
| Card Sorting Test (Berg) | Secondary outcome | ConductCognition |
| Mental Rotation | Secondary outcome | ConductCognition |
| Rapid Visual Information Processing | Secondary outcome | ConductCognition |
| Simple Reaction Time | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02432066
GET https://conductscience.org/api/trials/v1/NCT02432066/registered?page=2